These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
222 related articles for article (PubMed ID: 21372353)
41. Sleep disturbances in patients of liver cirrhosis with minimal hepatic encephalopathy before and after lactulose therapy. Singh J; Sharma BC; Puri V; Sachdeva S; Srivastava S Metab Brain Dis; 2017 Apr; 32(2):595-605. PubMed ID: 28070704 [TBL] [Abstract][Full Text] [Related]
42. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Lunia MK; Sharma BC; Sharma P; Sachdeva S; Srivastava S Clin Gastroenterol Hepatol; 2014 Jun; 12(6):1003-8.e1. PubMed ID: 24246768 [TBL] [Abstract][Full Text] [Related]
43. Rifaximin plus lactulose versus lactulose alone for reducing the risk of HE recurrence. Sanyal AJ; Kowdley KV; Reau NS; Pyrsopoulos NT; Allen C; Heimanson Z; Bajaj JS Hepatol Commun; 2024 Jun; 8(6):. PubMed ID: 38727685 [TBL] [Abstract][Full Text] [Related]
44. Diagnostic Performance of the ICD-10 Code K76.82 for Hepatic Encephalopathy in Patients With Cirrhosis. Ozturk NB; Jamil LH; Tapper EB Am J Gastroenterol; 2024 Feb; 119(2):364-366. PubMed ID: 37830544 [TBL] [Abstract][Full Text] [Related]
45. RiMINI - the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial. Schulz C; Schütte K; Kropf S; Schmitt FC; Vasapolli R; Kliegis LM; Riegger A; Malfertheiner P Trials; 2016 Feb; 17(1):111. PubMed ID: 26926775 [TBL] [Abstract][Full Text] [Related]
47. Efficacy of L-ornithine-L-aspartate as an adjuvant therapy in cirrhotic patients with hepatic encephalopathy. Abid S; Jafri W; Mumtaz K; Islam M; Abbas Z; Shah HA; Hamid S J Coll Physicians Surg Pak; 2011 Nov; 21(11):666-71. PubMed ID: 22078345 [TBL] [Abstract][Full Text] [Related]
48. Diabetes as a risk factor for hepatic encephalopathy in cirrhosis patients. Jepsen P; Watson H; Andersen PK; Vilstrup H J Hepatol; 2015 Nov; 63(5):1133-8. PubMed ID: 26206073 [TBL] [Abstract][Full Text] [Related]
49. Orthograde whole gut irrigation with mannite versus paromomycine + lactulose as prophylaxis of hepatic encephalopathy in patients with cirrhosis and upper gastrointestinal bleeding: results of a controlled randomized trial. Tromm A; Griga T; Greving I; Hilden H; Hüppe D; Schwegler U; Micklefield GH; May B Hepatogastroenterology; 2000; 47(32):473-7. PubMed ID: 10791216 [TBL] [Abstract][Full Text] [Related]
50. Linkage of gut microbiome with cognition in hepatic encephalopathy. Bajaj JS; Ridlon JM; Hylemon PB; Thacker LR; Heuman DM; Smith S; Sikaroodi M; Gillevet PM Am J Physiol Gastrointest Liver Physiol; 2012 Jan; 302(1):G168-75. PubMed ID: 21940902 [TBL] [Abstract][Full Text] [Related]
51. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy. Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842 [TBL] [Abstract][Full Text] [Related]
52. Minimal hepatic encephalopathy in cirrhosis- how long to treat? Goyal O; Sidhu SS; Kishore H Ann Hepatol; 2017 Jan-Feb 2017; 16(1):115-122. PubMed ID: 28051800 [TBL] [Abstract][Full Text] [Related]
53. The PROs and cons of crystalline lactulose for suspected covert HE among patients with cirrhosis and activity impairment: Are we using the right assessments? Jesudian AB; Fortune BE Hepatology; 2023 Oct; 78(4):1015-1016. PubMed ID: 37246443 [No Abstract] [Full Text] [Related]
54. [Hepatic encephalopathy – the acute management]. Wahlin S Lakartidningen; 2016 Mar; 113():. PubMed ID: 26978809 [TBL] [Abstract][Full Text] [Related]
55. Randomized controlled trial of polyethylene glycol versus lactulose for the treatment of overt hepatic encephalopathy. Shehata HH; Elfert AA; Abdin AA; Soliman SM; Elkhouly RA; Hawash NI; Soliman HH Eur J Gastroenterol Hepatol; 2018 Dec; 30(12):1476-1481. PubMed ID: 30234645 [TBL] [Abstract][Full Text] [Related]
56. [Hepatic encephalopathy and liver transplantation]. Fehérvári I; Nemes B; Görög D; Gerlei Z; Kóbori L Magy Seb; 2012 Apr; 65(2):58-62. PubMed ID: 22512880 [TBL] [Abstract][Full Text] [Related]
57. Is Lactulose Plus Rifaximin Better than Lactulose Alone in the Management of Hepatic Encephalopathy? Butt NI; Butt UI; Kakar AATK; Malik T; Siddiqui AM J Coll Physicians Surg Pak; 2018 Feb; 28(2):115-117. PubMed ID: 29394969 [TBL] [Abstract][Full Text] [Related]
58. Critical flicker frequency for diagnosis and assessment of recovery from minimal hepatic encephalopathy in patients with cirrhosis. Sharma P; Sharma BC; Sarin SK Hepatobiliary Pancreat Dis Int; 2010 Feb; 9(1):27-32. PubMed ID: 20133225 [TBL] [Abstract][Full Text] [Related]
59. Lactitol in the treatment of chronic hepatic encephalopathy--a randomized cross-over comparison with lactulose. Riggio O; Balducci G; Ariosto F; Merli M; Tremiterra S; Ziparo V; Capocaccia L Hepatogastroenterology; 1990 Oct; 37(5):524-7. PubMed ID: 2253931 [TBL] [Abstract][Full Text] [Related]
60. Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy. Moratalla A; Ampuero J; Bellot P; Gallego-Durán R; Zapater P; Roger M; Figueruela B; Martínez-Moreno B; González-Navajas JM; Such J; Romero-Gómez M; Francés R Liver Int; 2017 Feb; 37(2):212-223. PubMed ID: 27388776 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]